Healthcare Private Placement and M&A Transactions Review

Strategy | Financing | Macro & Markets

Share Silverwood Weekly Healthcare Market Update

Private Placement / Financing Transactions

Beren Therapeutics: The company raised $300 million in venture funding, in a combination of equity and debt, from Stern Stewart Ventures, Eisai, and Hercules Capital BDC on June 10, 2026. The company is a developer of therapeutic medicines intended for treating rare and severe diseases.SonoThera: The company raised $125 million of Series B venture funding in a deal led by Vida Ventures (Los Angeles) on June 10, 2026. The company is a developer of a nonviral gene therapy platform designed to provide ultrasound-mediated genetic medicines.CeQur Simplicity: The company raised CHF 79.8 million of Series E venture funding from undisclosed investors on June 9, 2026, putting the company’s pre-money valuation at CHF 222.7 million. The company is a developer of an insulin patch designed to simplify delivery for diabetes patients.City Therapeutics: The company raised $99.5 million of Series B venture funding from Regeneron Ventures, NYBC Ventures and The Invus Group on June 8, 2026. The company is an operator of a biotechnology business developing next-generation RNA interference medicines.Rylo: The company raised $85 million of venture funding in a deal led by Canaan Partners and General Catalyst on June 9, 2026, putting the company’s pre-money valuation at $415 million. The company is a developer of AI-powered communication tools for deaf and hard-of-hearing users, including call captioning and live transcription.Ethyreal Bio: The company raised $60 million of Series B venture funding in a deal led by Avoro Capital on June 10, 2026, putting the company’s pre-money valuation at $300 million. The company is a developer of precision therapies for thyroid eye disease and Graves’ disease, including anti-TSHR antibodies.Infinant Health: The company raised $39.3 million of venture funding from undisclosed investors on June 8, 2026. The company is a developer of infant microbiome products to support infant gut and immune health.Nventric: The company raised KRW 34.5 billion of Series C venture funding from Heungkuk Securities, Pacific Capital and Flexus Partners on June 10, 2026. The company is a developer of a medical device designed to remove blood clots that cause ischemic stroke.Fesarius Therapeutics: The company raised $20 million of Series A venture funding in a deal led by Jefferson Life Sciences on June 10, 2026. The company is a developer of bioregenerative medical technologies designed to advance wound care, reconstructive surgery, and regenerative medicine.Duke Street Bio: The company raised GBP 10.8 million of venture funding from undisclosed investors on June 11, 2026, putting the company’s pre-money valuation at GBP 97.8 million. The company is a developer of cancer drugs.Anodyne Nanotech: The company raised $12.6 million of venture funding from undisclosed investors on June 11, 2026. The company is a developer of transdermal drug delivery technology designed to reformulate clinically validated molecules into needle-free therapeutics for chronic diseases.Zumutor Biologics: The company raised $7.3 million of Series B venture funding from Premji Invest, Accel and Bharat Innovation Fund on June 13, 2026. The company is an operator of an immuno-oncology platform developing targeted NK cell therapeutics and antibody drugs that modulate innate immunity and the tumor microenvironment.Rejuvenate Bio: The company raised $6 million of Series B venture funding in a deal led by VCapital on June 8, 2026, putting the company’s pre-money valuation at $60 million. The company is a developer of a biotechnology platform designed to increase healthspan and extend lifespan through novel gene therapies.Magvation: The company raised $5.5 million of venture funding from undisclosed investors on June 8, 2026. The company is a developer of an AI-powered collaborative robot designed to reduce preventable error-causing factors in the operating room.Aton Health: The company raised an undisclosed amount of Series A venture funding in a deal led by Shore Capital Partners on June 12, 2026. The company is a developer of a real-world evidence platform for observational healthcare research embedded in routine clinical care.Element Biosciences: The company raised Series E venture funding from Samsung Electronics and other undisclosed investors on June 9, 2026. The company is a developer of genetic analysis tools for research and diagnostic applications.Petal Surgical: The company raised an undisclosed amount of venture funding in a deal led by Blue Pool Capital on June 14, 2026. The company is a developer of focused-ultrasound surgical technology for incisionless procedures.ViViRA: The company raised an undisclosed amount of venture funding in a deal led by BonVenture, IBB Ventures and Patrick Palacin on June 10, 2026. The company is a developer of a digital therapeutic app for treating musculoskeletal pain through guided exercise therapy.

M&A Transactions

Nuvalent / GSK: The company reached a definitive agreement to be acquired by GSK for $10.6 billion on June 9, 2026. The company is a clinical-stage biopharmaceutical company developing precisely targeted cancer therapies, with lead programs in ROS1- and ALK-positive NSCLC.Masimo / Danaher: The company was acquired by Danaher for $9.9 billion on June 10, 2026. The company is a medical technology business developing noninvasive patient monitoring technologies, hospital automation systems, connectivity solutions, and remote monitoring devices.Ajax Therapeutics / Lilly USA: The company was acquired by Lilly USA for $2.3 billion on June 13, 2026. The company is a developer of targeted therapy drugs designed for the treatment of hematologic cancers.KalVista / Chiesi Farmaceutici: The company was acquired by Chiesi Farmaceutici for $1.9 billion on June 11, 2026. The company is a pharmaceutical busines developing oral therapies for hereditary angioedema and other rare diseases.Riverpoint Medical / Novanta: The company reached a definitive agreement to be acquired by Novanta for $1.5 billion on June 9, 2026. The company is a manufacturer of medical devices intended for orthopedics, oncology, ophthalmology, cardiovascular and other related markets.Vega Therapeutics / Incyte: The company reached a definitive agreement to be acquired by Incyte for $2 billion on June 8, 2026. The company is an operator of a clinical-stage biotechnology business intended to focus on addressing overlooked needs in rare blood disorders.Transcend Therapeutics / Otsuka Pharmaceutical: The company was acquired by Otsuka Pharmaceutical, a subsidiary of Otsuka Holdings, for $1.2 billion on June 12, 2026. The company is an operator of a neuroscience-focused clinical-stage company intended to develop psychoactive medicines for neuropsychiatric disease.FireFly Bio / Johnson & Johnson: The company reached a definitive agreement to be acquired by Johnson & Johnson for $1 billion on June 8, 2026. The company is an operator of an antibody-drug conjugate-based healthcare platform intended to treat cancer using degradable proteins.Emalex Biosciences / Teva Pharmaceutical Industries: The company was acquired by Teva Pharmaceutical Industries for up to $900 million on June 10, 2026. The company is a developer of biopharmaceutical drugs designed to diagnose and cure central nervous system disorders and rare and orphan neurological conditions.Scientia Vascular / Medtronic: The company was acquired by Medtronic for $550 million on June 12, 2026. The company is a manufacturer of endovascular medical devices designed for neuro, peripheral, and coronary vascular access applications.Jaide Health / AMN Healthcare Services: The company was acquired by AMN Healthcare Services for $3 million on June 9, 2026. The company is a developer of a real-time AI-driven platform designed to provide HIPAA-compliant medical interpretation and translation.Azora Therapeutics / Adial Pharmaceuticals: The company was acquired by Adial Pharmaceuticals for an undisclosed amount on June 11, 2026. The company is a developer of a therapeutic medicine intended to treat serious, debilitating inflammatory diseases.Camascope / Brighton Park Capital: The company was acquired by Person Centred Software, via its financial sponsor Brighton Park Capital and Cow Corner Investing, through an LBO on June 10, 2026 for an undisclosed amount. The company is a developer of an electronic medication administration platform for medication safety and care delivery in health and social care settings.Proteintech Genomics / 10x Genomics: The Proteintech Genomics division of the Proteintech Group, was acquired by 10x Genomics for an undisclosed amount on June 09, 2026. The company is a developer of multiomic solutions designed to empower the research community with single-cell and spatial analysis tools.Standard BioTools / Treeline Biosciences: The company reached a definitive agreement to be acquired by Treeline Biosciences through a reverse merger, resulting in the combined entity trading on the NASDAQ Stock Exchange under the ticker symbol TRLN on June 8, 2026. The company develops, manufactures, and sells life sciences technologies that help biomedical researchers develop medicines faster.

Source: Pitchbook Data, Inc.
Connect on LinkedIn with Jonathan Hodson-Walker